Navigation Links
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Date:5/15/2008

- Trial Results Confirm Efficacy for Population Most Affected by Disease -

WAYNE, N.J. and EMERYVILLE, Calif., May 16 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that Nexavar(R) (sorafenib) tablets significantly improved overall survival by 47.3 percent (HR=0.68; p-value=0.014) in patients in the Asia-Pacific region with advanced hepatocellular carcinoma (HCC), or primary liver cancer versus those receiving placebo. Nexavar also significantly improved time to progression in these patients by 74 percent (HR=0.57; P=0.001). These data were presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) and further confirm Nexavar's efficacy in liver cancer.

The international, Phase 3, randomized trial evaluated efficacy and safety of Nexavar versus placebo in 226 Asian patients with advanced HCC who had not received prior systemic therapy. The study was designed to compare overall survival, time to progression, time to symptomatic progression, response as defined by RECIST criteria and safety in patients receiving Nexavar versus placebo. Median overall survival was 6.5 months in patients treated with Nexavar versus 4.2 months for those taking placebo. The survival benefit was seen across multiple patient subsets analyzed, including age, extrahepatic spread and/or macroscopic vascular invasion.

"Liver cancer in the Asia-Pacific region continues to grow because of a high incidence of chronic hepatitis B viral infections, which now impact approximately 275 million people in the region," said Ann-Lii Cheng, MD, PhD, Department of Internal Medicine and Department of Oncology, National Taiwan University Hospital, Taipei, T
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
2. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
3. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
4. Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
5. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
6. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
7. Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
8. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
9. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
10. Orqis(R) Medicals Cancion(R) System Significantly Increases Cardiac Performance
11. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... -- Medela announced today that it has reached a five-year ... the exclusive distributor of the ABC Enteral Feeding Pump ... Pump. Through this agreement, Medela will be in a ... by offering a comprehensive set of products and programs. ... to the delivery of human milk to at-risk infants. ...
(Date:9/23/2014)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... focus on China , announces the ... and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. to ... connection with the recently announced acquisition of greater ...
(Date:9/23/2014)... CARLOS, Calif. , Sept. 23, 2014 /PRNewswire/ ... company, today confirmed the initiation of human safety ... forms of addiction. A single dose of 18-MC, ... safety study conducted by Savant,s South American partner, ... experimental drug. Savant HWP plans to develop 18-MC ...
Breaking Medicine Technology:Medela Enters Exclusive Enteral Feeding Pump Agreement with Atlanta Biomedical Company 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 2Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 3
... Health Care Decisions?CHARLOTTE, N.C., March 24 For anyone ... life at any age, or to turn around current ... have the answers right in your own backyard.The Charlotte ... and wellness event in the queen city. With expert ...
... Calixa Therapeutics Inc. today announced positive results from a ... antibiotic with excellent in vitro anti-pseudomonal activity. ... that CXA-101 was well tolerated, with a clinical and ... antibiotics. No dose-limiting toxicity was observed, even at the ...
Cached Medicine Technology:Anti-Aging Expo & Symposium Showcases in Charlotte on March 28th 2Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity 2
(Date:9/23/2014)... 2014 (HealthDay News) -- The U.S. National Institutes ... funding in scientific trials to encourage researchers to ... The supplemental monies were provided to 82 ... immunology, cardiovascular physiology, neural circuitry, and behavioral health, ... "This funding strategy demonstrates our commitment to moving ...
(Date:9/23/2014)... Center have published the first study to extensively ... The Journal of Allergy and Clinical Immunology ... that has high levels of eosinophils in the ... allergy-associated-immune mechanisms and has a gene expression pattern ... related disorder, eosinophilic esophagitis (EoE). , Eosinophilic ...
(Date:9/23/2014)... 23, 2014) Laparoscopic cholecystectomy, a minimally invasive procedure to ... abdominal surgeries in the U.S. Yet medical centers around ... with some moving patients quickly into surgery while others ... the American Journal of Surgery , researchers found ... rather than rushing the patients into the operating room ...
(Date:9/23/2014)... Act "Obamacare" was signed into law in ... healthcare system since the 1960s. Designed to provide medical ... as an unwarranted intrusion into the affairs of private ... of healthcare systems in six Western countries, published last ... a move away from privatized medicine toward state-sponsored healthcare ...
(Date:9/23/2014)... 2014 Royal Sport Ultra Clean 100 ... LTD family of premium sports nutrition products. Its gluten ... Whey protein without artificial colors or dyes, fillers, added ... available on shelves at select GNC retailers, on GNC.com, ... is offering a limited time special on its products. ...
Breaking Medicine News(10 mins):Health News:NIH Adds $10M to Encourage Gender Balance in Clinical Trials 2Health News:Advancing the understanding of an understudied food allergy disorder 2Health News:Advancing the understanding of an understudied food allergy disorder 3Health News:Study finds gallbladder surgery can wait 2Health News:Life, liberty, and the pursuit of healthcare? 2Health News:Sports Nutrition Brand, Royal Sport LTD, Introduces 'Clean,' Gluten Free Protein Supplement, Royal Sport Ultra Clean 100™ 2
... intensive therapy works well, study finds , THURSDAY, Aug. ... (RA) who respond poorly to standard treatment with methotrexate ... (TNF) blockers, a Swedish study suggests. , Previous research ... patients have a good response to methotrexate therapy and ...
... , , MISSION VIEJO, Calif., ... the parent company of the Ensign(TM) group of skilled nursing, rehabilitative care ... quarter of fiscal year 2009. , , (Logo: ... Include: , , Total revenue was ...
... , , RANCHO CORDOVA, Calif., ... ), a leading supplier of innovative products for processing and storing ... BMC ("Res-Q") System, an automated cell processing medical device for the ... , , The Res-Q System processes bone ...
... American Health Assistance Foundation Researcher Is Featured Facilitator , ... Health Assistance Foundation and Asbury Methodist Village are partnering to host a ... Project to bring awareness to the community about this devastating disease, ... Part one of the Momentum in Science ...
... ... The Angelman Syndrome Foundation, www.angelman.org , announced the ... direct the organization,s rapidly increasing research funding. The ATRI will also ... scientists worldwide to share discoveries and treatments for this neuro-genetic disorder. ...
... BETHESDA, Md., Aug. 6 /PRNewswire-Asia/ -- , ... CHDX ), a leading,independent American provider ... Republic of China, today announced that the Company,s,Western-style ... a comprehensive, international-standard oncology program, called "New,Hope," at ...
Cached Medicine News:Health News:TNF Blockers May Help Some With Rheumatoid Arthritis 2Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 2Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 3Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 4Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 5Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 6Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 7Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 8Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 9Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 10Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 11Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 12Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 13Health News:ThermoGenesis Announces Launch of Res-Q System; New Device Expands Company's Presence in Bone Marrow Sector 2Health News:ThermoGenesis Announces Launch of Res-Q System; New Device Expands Company's Presence in Bone Marrow Sector 3Health News:American Health Assistance Foundation & Asbury Methodist Village to Host Special Community Screening and Discussion of the HBO Series, The Alzheimer's Project 2Health News:American Health Assistance Foundation & Asbury Methodist Village to Host Special Community Screening and Discussion of the HBO Series, The Alzheimer's Project 3Health News:Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts 2Health News:Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts 3Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 2Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 3Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 4
... 4, 8, or 12 channel pipettors. Angled ... nearly all of the solution. Corners have ... Made of natural virgin polystyrene containing no ... 152 mm L x 35 mm H ...
Volume: 5 ml; Volume Graduation: 1/10 ml...
... for use with measuring pipettes, enables you to ... works with all types of glass or plastic ... to 100 mL.Gilsons Pipette Aid is equipped with ... protect the mechanism of the device from contamination ...
Application: Safe and convenient filling and dispensing of glass and plastic pipets....
Medicine Products: